Companion Diagnostics: Technologies and Markets

Report Code: BIO077B

Publish Date: Nov 2013

Publisher: BCC Publishing

Category: Cell Biology

Customize This Report

Single User License: $2750

Member Price: FREE

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global companion diagnostics market reached $1.1 billion in 2012. The market is expected to grow to $1.2 billion in 2013 and $3.5 billion in 2018 with a compound annual growth rate (CAGR) of 23.9%.

Report Includes

  • An overview of the market for companion diagnostics, including existing products on the market and detailed analysis of the competitive environments.
  • Analyses of market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of the current state of the industry, new technologies in assay development, and potential novel commercial venues in this area of the healthcare industry.
  • Identification of major commercial sectors in companion diagnostics: oncology related products vs. cardiovascular diseases and other segments.
  • Comprehensive company profiles of major players, as well as a list of current companies that have new companion diagnostics products in development.

Report Scope

Personalized medicine is relatively new to the market research report format and provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The geographic scope of this study covers U.S. and global companies. The report identifies major commercial sectors in companion diagnostics, including oncology-related products versus cardiovascular diseases. It describes current products in each area, identifies current market participants, and most importantly, notes the trends that are likely to affect further product development in this area. The report also provides information regarding less-developed sectors of this market, along with a list of current companies that have new companion diagnostic products in development.

Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Analyst Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology and industrial assay development and drug manufacturing. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Companion Diagnostics: Technologies and Markets187Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW, STRUCTURE AND SIGNIFICANCE OF THE COMPANION DIAGNOSTICS INDUSTRY 17Free
Chapter- 4: BIOMARKER AND DIAGNOSTICS MARKETS AS THE BASIS FOR THE COMPANION DIAGNOSTICS INDUSTRY 8Free
Chapter- 5: EFFECT OF THE REGULATORY ASPECT, COST AND REIMBURSEMENT POLICIES ON THE COMPANION DIAGNOSTICS INDUSTRY6Free
Chapter- 6: EFFECT OF THE PERSONALIZED MEDICINE TREND ON PRODUCT DEVELOPMENT IN OTHER INDUSTRIES9Free
Chapter- 7: PATENT APPLICATIONS FOR COMPANION DIAGNOSTICS AND BIOMARKERS3Free
Chapter- 8: CURRENT TECHNIQUES AND TECHNOLOGIES FOR COMPANION DIAGNOSTICS6Free
Chapter- 9: GENETIC KNOWLEDGE AND CLINICIAN OPINIONS AS DRIVERS FOR THE COMPANION DIAGNOSTICS MARKET3Free
Chapter- 10: COMPANION DIAGNOSTICS INDUSTRY MARKET EVALUATIONQIAGEN17Free
Chapter- 11: COMPANION DIAGNOSTICS INDUSTRY OVERVIEW IN DIFFERENT RESEARCH AREAS88Free
Chapter- 12: MARKET SUMMARY 5Free
Chapter- 13: C. CRAMER & CO. GMBH8Free
Chapter- 14: COMPANIES MENTIONED IN THIS REPORT12Free
Published - Nov-2010| Analyst - Marianna Tcherpakov| Code - BIO077A

Report Highlights

 
  • Oncotype Dx, although not FDA-approved, is still a lead product in the breast cancer diagnosis sector.  Oncotype Dx is reimbursed by most insurance companies and therefore enjoys an increase in its sales number every year.  Valued at $170 million in 2010, analysts believe that by 2015, Oncotype Dx for breast cancer risk recurrence and drug regimen may reach $300 million, a compound annual growth rate (CAGR) of 12%.
  • The approval of Selzentry for first time HIV patients is creating new opportunity for the assay Trofile, a companion diagnostic to Selzentry (Celsentri outside U.S.). As a result, Trofile is expected to reach an estimated $34 million by 2015, from $24 million in 2010, a compound annual growth rate (CAGR) of 7.2%.

Related Reports

Cancer Profiling and Pathways: Technologies and Global Markets

Published - Jan 2014 | Publisher - Usha Nagavarapu | Code - BIO073B

The global market for cancer profiling technologies reached $26.1 billion in 2012. This market is expected to grow to nearly $30.1 billion in 2013 and $54.8 billion in 2018, a compound annual growth rate (CAGR) of 12.8% over the five-year period, 2013 to 2018.

Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery

Published - Jun 2013 | Publisher - Marianna Tcherpakov | Code - PHM066B

The global market for ubiquitin proteasome research and development was estimated at nearly $2.9 billion in 2013. The market should total more than $5.5 billion by 2018, and have a five-year compound annual growth rate (CAGR) of 14.2% from 2013 to 2018.

Alzheimer's Disease Therapeutics and Diagnostics: Global Markets

Published - May 2013 | Publisher - Yogita Zutshi | Code - PHM062B

The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.

Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets

Published - Oct 2012 | Publisher - George W. Jackson | Code - BIO071B

The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.

Recent Reports

Life Science Tools and Reagents: Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO083E

The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.

RNAi Technologies and Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO127C

The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.

Metabolomics: Technologies and Global Markets

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO055E

The global market for metabolomics technologies is expected to grow from $16.4 billion in 2024 and is projected to reach $30.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% during the forecast period of 2024 to 2029.

Global Recombinant Proteins Market

Published - Jul 2024 | Publisher - BCC Publishing | Code - BIO254A

The global market for recombinant proteins is estimated to increase from $132.4 billion in 2023 to reach $203.6 billion by 2029, at a compound annual growth rate (CAGR) of 7.5% from 2024 through 2029.

Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics

Published - Jun 2024 | Publisher - Gundreddy Gopinadh | Code - BIO157C

The global market for polymerase chain reaction for point-of-care diagnostics is expected to grow from $1.6 billion in 2024 to $2.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Top Trending Reports

Global Market for Cell and Gene Therapy

Published - Apr 2024 | Publisher - BCC Publishing | Code - BIO225B

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

Sensors: Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - IAS006P

The global market for sensors is estimated to increase from $179.7 billion in 2023 to reach $300.5 billion by 2029, at a compound annual growth rate (CAGR) of 8.9% from 2024 through 2029.

Gene Synthesis: Technologies and Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - BIO251A

The global market for Gene Synthesis is estimated to increase from $2.0 billion in 2023 to reach $4.1 billion by 2028, at a compound annual growth rate (CAGR) of 15.8% from 2023 through 2028.

Medical Robotics and Computer-assisted Surgery: The Global Market

Published - Jun 2024 | Publisher - BCC Publishing | Code - HLC036J

The global market for medical robotics and computer-assisted surgery is expected to grow from $11.5 billion in 2023 and projected to reach $19.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.

Water Filtration: Global Markets

Published - Jun 2024 | Publisher - BCC Publishing | Code - MST080B

The global market for water filtration is expected to grow from $10.5 billion in 2024 and is projected to reach $19.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.5% during the forecast period of 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Companion Diagnostics: Technologies and Markets
Customize Report